Clinuvel Pharmaceuticals Ltd
ASX:CUV

Watchlist Manager
Clinuvel Pharmaceuticals Ltd Logo
Clinuvel Pharmaceuticals Ltd
ASX:CUV
Watchlist
Price: 12.15 AUD 0.33% Market Closed
Market Cap: 608.2m AUD
Have any thoughts about
Clinuvel Pharmaceuticals Ltd?
Write Note

Clinuvel Pharmaceuticals Ltd
Long-Term Debt

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Clinuvel Pharmaceuticals Ltd
Long-Term Debt Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Long-Term Debt CAGR 3Y CAGR 5Y CAGR 10Y
Clinuvel Pharmaceuticals Ltd
ASX:CUV
Long-Term Debt
AU$509.9k
CAGR 3-Years
-21%
CAGR 5-Years
24%
CAGR 10-Years
N/A
Immutep Ltd
ASX:IMM
Long-Term Debt
AU$1.4m
CAGR 3-Years
-19%
CAGR 5-Years
-29%
CAGR 10-Years
N/A
Mesoblast Ltd
ASX:MSB
Long-Term Debt
$102.4m
CAGR 3-Years
27%
CAGR 5-Years
9%
CAGR 10-Years
N/A
CSL Ltd
ASX:CSL
Long-Term Debt
$11.2B
CAGR 3-Years
28%
CAGR 5-Years
22%
CAGR 10-Years
20%
Telix Pharmaceuticals Ltd
ASX:TLX
Long-Term Debt
AU$15.9m
CAGR 3-Years
123%
CAGR 5-Years
93%
CAGR 10-Years
N/A
PYC Therapeutics Ltd
ASX:PYC
Long-Term Debt
AU$803k
CAGR 3-Years
14%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Clinuvel Pharmaceuticals Ltd
Glance View

Market Cap
608.4m AUD
Industry
Biotechnology

Clinuvel Pharmaceuticals Ltd. operates as a biopharmaceutical company. The company is headquartered in Melbourne, Victoria. The company went IPO on 2001-02-13. The firm is focused on developing and commercializing treatments for patients with genetic, metabolic, and life-threatening disorders, as well as healthcare solutions for the general population. The Company’s principal activity consists of commercializing and distribution in Europe and the United States of its drug candidate SCENESSE for the treatment of a rare, genetic metabolic disorder erythropoietic protoporphyria (EPP). The company is also focused on developing and commercializing SCENESSE as a combination with narrowband ultraviolet B (NB-UVB) phototherapy and topical pharmaceutical formulations of melanocortin analogues for the treatment of the skin depigmentation disorder vitiligo. Its research and development of PRENUMBRA, a new liquid formulation of afamelanotide for the treatment of acute disorders and vascular anomalies.

CUV Intrinsic Value
20.89 AUD
Undervaluation 42%
Intrinsic Value
Price

See Also

What is Clinuvel Pharmaceuticals Ltd's Long-Term Debt?
Long-Term Debt
509.9k AUD

Based on the financial report for Jun 30, 2024, Clinuvel Pharmaceuticals Ltd's Long-Term Debt amounts to 509.9k AUD.

What is Clinuvel Pharmaceuticals Ltd's Long-Term Debt growth rate?
Long-Term Debt CAGR 5Y
24%

Over the last year, the Long-Term Debt growth was -27%. The average annual Long-Term Debt growth rates for Clinuvel Pharmaceuticals Ltd have been -21% over the past three years , 24% over the past five years .

Back to Top